SUNNYVALE, Calif., July 24, 2019 /PRNewswire/ -- Accuray
Incorporated (NASDAQ: ARAY) announced today that studies validating
the benefits of CyberKnife® and
Radixact® System software innovations were shared
by prominent physicists at the recent 61st annual
meeting of the American Association of Physicists in Medicine
(AAPM). These product enhancements are designed to make it faster
and easier for clinicians to deliver precise radiation treatments
to more patients each day.
"Accuray is dedicated to providing clinicians with solutions
that enable them to achieve their clinical goals for patients at
every stage of their cancer treatment journey," said Fabienne
Hirigoyenberry-Lanson, Ph.D., vice president of global medical and
scientific affairs at Accuray. "The clinical results shared at this
year's AAPM meeting showcase the breadth of innovation achieved in
partnership with our customers, and the benefits that Accuray
products can deliver to clinicians and their patients, now and into
the future."
Research highlights include:
CyberKnife VOLO™ Optimizer significantly reduces
treatment planning and estimated treatment delivery times
- Studies demonstrate benefits of the CyberKnife VOLO Optimizer
across multiple tumor types.
-
- A planning comparison study showed that, for prostate SBRT
patients previously treated with an InCise™ Multileaf Collimator
(MLC), the VOLO Optimizer allowed clinicians to develop optimal
plans eight times faster (62 minutes versus 8 hours), while
simultaneously reducing average estimated treatment delivery time
by 31 percent. Researchers at Erasmus
University Medical Center in Rotterdam, the Netherlands, conducted the
study.
- A team of researchers at Stanford
University compared plans generated with the CyberKnife VOLO
Optimizer and Sequential Optimizer in patients with tumors
classified as simple brain, complex brain or complex spine. All
estimated treatment delivery times were reduced using VOLO, with
time savings ranging from 14 percent (for simple brain cases using
the Iris collimator) to 50 percent (for complex brain cases using
the InCise MLC).
Synchrony® for the Radixact System automates
real-time motion tracking and correction while targets
move
- University of Wisconsin – Madison
and Accuray Incorporated researchers evaluated the potential of the
motion synchronization technology developed for the Radixact System
to track and correct for tumor motion during delivery. Patient
plans were delivered to a phantom and the dose delivered was
compared to the planning dose. Results for the sample plan
presented showed that the motion synchronization technology was
able to effectively track and correct for the phantom motion.
CTrue™ IR Improves image quality
- The clinical impact of using CTrue IR (Iterative
Reconstruction) MVCT images for image-guided radiation therapy
(IGRT) was analyzed by researchers at the Medical College of Wisconsin. MVCT images acquired
on the Radixact System were reconstructed with IR and standard
algorithms. CTrue IR improved soft-tissue contrast and
substantially reduced image noise, enhancing image quality.
Investigators also found that patient alignment during IGRT was
easier to achieve and more accurate with CTrue IR MVCT than with
standard MVCT.
Radixact System PreciseART® makes adaptive
re-planning easier
- Medical College of Wisconsin
researchers investigated the rate of offline adaptive re-planning
in their clinic with and without the use of technology enabling
them to perform automated dose calculation and trending. The
re-planning rate for patients enrolled in the Radixact System
PreciseART® Option, which automatically calculates dose,
trends daily dose changes, and triggers adaptive re-planning based
on clinician-established criteria, was compared to the estimated
re-planning rate for patients treated on VMAT and other systems
without similar automated capabilities. Automated tools available
with PreciseART® increased the frequency of offline
adaptive re-planning over the course of the radiation therapy,
indicating it better identified interfraction changes for which
re-planning was clinically beneficial.
About Accuray
Accuray Incorporated (Nasdaq: ARAY) develops, manufactures and
sells radiotherapy systems that are intended to make cancer
treatments shorter, safer, personalized and more effective,
ultimately enabling patients to live longer, better lives. Our
radiation treatment delivery systems in combination with
fully-integrated software solutions set the industry standard for
precision and cover the full range of radiation therapy and
radiosurgery procedures. For more information, please visit
www.accuray.com or follow us on Facebook, LinkedIn, Twitter and
YouTube.
Safe Harbor Statement
Statements made in this press release that are not statements of
historical fact are forward-looking statements and are subject to
the "safe harbor" provisions of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements in this press
release relate, but are not limited, to clinical applications,
clinical results, patient experiences and outcomes, and the
potential benefits of Accuray products. These forward-looking
statements involve risks and uncertainties. If any of these risks
or uncertainties materialize, or if any of the company's
assumptions prove incorrect, actual results could differ materially
from the results expressed or implied by these forward-looking
statements. These risks and uncertainties include, but are not
limited to, the company's ability to achieve widespread market
acceptance of its products, including new product offerings and
improvements; the company's ability to develop new products or
improve existing products to meet customers' needs; the company's
limited long-term clinical data supporting the safety and efficacy
of its products, including product improvements, for certain users
and such other risks identified under the heading "Risk Factors" in
the company's quarterly report on Form 10-Q, filed with the
Securities and Exchange Commission (the "SEC") on May 9, 2019 and as updated periodically with the
company's other filings with the SEC.
Forward-looking statements speak only as of the date the
statements are made and are based on information available to the
company at the time those statements are made and/or management's
good faith belief as of that time with respect to future events.
The company assumes no obligation to update forward-looking
statements to reflect actual performance or results, changes in
assumptions or changes in other factors affecting forward-looking
information, except to the extent required by applicable securities
laws. Accordingly, investors should not put undue reliance on any
forward-looking statements.
Media:
Beth Kaplan
Public Relations Director, Accuray
+1 (408) 789-4426
bkaplan@accuray.com
Jayme Maniatis
MSLGROUP
+1 (781) 684-6610
accuray@mslgroup.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/new-data-demonstrating-benefits-of-accuray-software-solutions-presented-at-the-annual-meeting-of-the-american-association-of-physicists-in-medicine-300889972.html
SOURCE Accuray Incorporated